• Medicxi portfolio company Vaderis Therapeutics raised USD 152 million in an oversubscribed Series B private placement co-led by Goldman Sachs Alternatives, TCGX.
• Proceeds fund operations through regulatory submissions, targeting potential U.S. approval for engasertib in hereditary hemorrhagic telangiectasia.
• Vaderis launched the global Phase 3 HEROIC trial for once-daily oral engasertib, an investigational allosteric AKT inhibitor, in moderate-to-severe HHT.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicxi Ventures Management Jersey Ltd. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein.